Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

by Turner, Nicholas C. , Schutzman, Jennifer L. , Leung, Roland , Lei, Guiyuan , Sunpaweravong, Patrapim , Thanopoulou, Eirini , Song, Chunyan , Saura, Cristina , Nowecki, Zbigniew , Shankar, Noopur , Li, Huiping , Schmid, Peter , Loi, Sherene , Loibl, Sibylle , Stout, Thomas J. , Juric, Dejan , Zhang, Qingyuan , Kalinsky, Kevin , Musolino, Antonino , Hutchinson, Katherine E. , Im, Seock-Ah , Jhaveri, Komal L.

in 1-Phosphatidylinositol 3-kinase / Adjuvants / Adult / Adverse events / Aged / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Antitumor activity / Breast Cancer / Breast Neoplasms - drug therapy / Breast Neoplasms - genetics / Breast Neoplasms - mortality / Breast Neoplasms - pathology / Breast Neoplasms, Male - drug therapy / Breast Neoplasms, Male - genetics / Breast Neoplasms, Male - mortality / Breast Neoplasms, Male - pathology / Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors / Class I Phosphatidylinositol 3-Kinases - genetics / Clinical medicine / Clinical trials / Collaboration / Cyclin-dependent kinases / Diarrhea / Double-Blind Method / Drug dosages / Endocrine therapy / ErbB-2 protein / Estrogens / Female / Fulvestrant / Hematology / Humans / Hyperglycemia / Imidazoles - administration & dosage / Imidazoles - adverse effects / Kaplan-Meier Estimate / Kinases / Male / Medical prognosis / Metastases / Metastasis / Middle Aged / Mutation / Neutropenia / Oncology / Oxazoles - administration & dosage / Oxazoles - adverse effects / Patients / Phosphoinositide-3 Kinase Inhibitors - administration & dosage / Phosphoinositide-3 Kinase Inhibitors - adverse effects / Piperazines - adverse effects / Piperazines - therapeutic use / Placebos / Progression-Free Survival / Pyridines - adverse effects / Pyridines - therapeutic use / Stomatitis / Survival / Treatments in Oncology / Tumors

2024

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

2024

Confirm

Do you wish to request the book?

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

2024

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

Turner, Nicholas C.,

Schutzman, Jennifer L.,

Leung, Roland,

Lei, Guiyuan,

Sunpaweravong, Patrapim,

Thanopoulou, Eirini,

Song, Chunyan,

Saura, Cristina,

Nowecki, Zbigniew,

Shankar, Noopur,

Li, Huiping,

Schmid, Peter,

Loi, Sherene,

Loibl, Sibylle,

Stout, Thomas J.,

Juric, Dejan,

Zhang, Qingyuan,

Kalinsky, Kevin,

Musolino, Antonino,

Hutchinson, Katherine E.,

Im, Seock-Ah,

Jhaveri, Komal L.

2024

Overview

In PIK3CA -mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer, inavolisib plus palbociclib–fulvestrant led to significantly longer progression-free survival than placebo plus palbociclib–fulvestrant.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

1-Phosphatidylinositol 3-kinase

/ Adjuvants

/ Adult

/ Adverse events

/ Aged

/ Antineoplastic Combined Chemotherapy Protocols - adverse effects

/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use